BRAINSTORM CELL THERAPEUTICS INC. (BCLI) - Dilution Analysis

10-Q filing | 11.0M shares outstanding

10-K filing | 11.0M shares outstanding

10-Q filing | 11.0M shares outstanding

10-Q filing | 10.4M shares outstanding

S-3 filing: The filing relates to the offer and resale by the selling stockholder of up to 2,762,766 shares of common stock underlying common stock purchase warrants issued to the Selling Stockholder on April 1, 2025.

10-Q filing | 7.9M shares outstanding

8-K filing: Brainstorm Cell Therapeutics, Inc. entered into an inducement agreement with a holder to exercise existing warrants to purchase up to 1,381,383 shares of the company's common stock for gross proceeds of approximately $1.64 million. ($1.64M proceeds)

10-K filing | 6.1M shares outstanding

10-Q filing | 5.7M shares outstanding

8-K filing: Stock split one-for-fifteen | Outstanding: 79,646,942 → 5,309,796

S-3/A filing: This S-3/A filing relates to the resale of up to 16,666,667 shares of common stock underlying warrants issued on June 28, 2024, to a selling stockholder, with the warrants exercisable beginning December 28, 2024, at an exercise price of $0.3912 per share.

S-3 filing: Resale of up to 16,666,667 shares of common stock underlying common stock purchase warrants issued in a private placement.

S-3 filing: Brainstorm Cell Therapeutics Inc. may from time to time issue up to $172,561,230 in aggregate principal amount of common stock, debt securities, warrants and/or units. They are also offering common stock through an at the market offering for up to $5,776,035 at $0.3139 per share.

10-Q filing | 79.6M shares outstanding

8-K filing: Brainstorm Cell Therapeutics Inc. sold 7,918,764 shares of common stock, pre-funded warrants to purchase up to 3,192,347 shares of common stock, and unregistered warrants to purchase up to 16,666,667 shares of common stock at a purchase price of $0.36 per share, yielding gross proceeds of approximately $4.0 million. ($4.0M proceeds)

10-Q filing | 64.7M shares outstanding

10-K filing | 60.5M shares outstanding

10-Q filing | 45.3M shares outstanding

10-Q filing | 38.2M shares outstanding

8-K filing: Brainstorm Cell Therapeutics Inc. entered into a Securities Purchase Agreement for a public offering of 4,054,055 shares of common stock and warrants at $1.85 per share, with gross proceeds of approximately $7.5 million. ($15.0M proceeds)

10-Q filing | 36.7M shares outstanding

10-K filing | 36.5M shares outstanding

10-Q filing | 36.5M shares outstanding

10-Q filing | 36.5M shares outstanding

10-Q filing | 36.4M shares outstanding

10-K filing | 36.2M shares outstanding

10-Q filing | 36.1M shares outstanding

S-3 filing: The company intends to offer and sell up to $200,000,000 in aggregate principal amount of common stock, debt securities, warrants and/or units in one or more offerings.

10-Q filing | 36.3M shares outstanding

10-Q filing | 36.3M shares outstanding

10-K filing | 35.2M shares outstanding

10-Q filing | 31.6M shares outstanding

8-K filing: Brainstorm Cell Therapeutics Inc. entered into an Amended and Restated Distribution Agreement with SVB Leerink LLC and Raymond James & Associates, Inc. to sell shares of the Company's common stock having an aggregate offering amount of up to $45,000,000. ($23.11M proceeds)

10-Q filing | 29.7M shares outstanding

10-Q filing | 29.4M shares outstanding

8-K filing: On March 9, 2020, the Compensation Committee authorized a grant to Ralph Kern of a stock option to purchase up to 80,000 shares of Company common stock, and authorized the grant of options to purchase up to an aggregate of 350,000 shares of Company common stock to employees.

8-K filing: Brainstorm Cell Therapeutics Inc. entered into a distribution agreement to sell up to $50,000,000 of common stock and closed a $10,000,000 registered direct offering of 1,250,000 shares of common stock at $8.00 per share. ($10.0M proceeds)

8-K filing: Brainstorm Cell Therapeutics Inc. entered into a Securities Purchase Agreement with Abbhi Investments, LLC, for a Registered Direct Offering of 1,250,000 shares of common stock at $8.00 per share, and agreed to issue a warrant to purchase 250,000 shares of common stock at an exercise price of $15.00 per share. ($10.0M proceeds)

10-K filing | 26.2M shares outstanding